US2006263376A1PendingUtilityA1
Pharmaceutical composition comprising PIM-activated NKT cells, and use thereof in therapy
Est. expiryApr 19, 2019(expired)· nominal 20-yr term from priority
A61P 35/00A61P 31/04A61K 31/685A61K 35/17
44
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
The invention concerns a pharmaceutical composition comprising at least a PIM-activated NKT cell and the use of at least one PIM and/or a PIM-activated NKT cell for treating a disease for which a granulomatous type of immune response is desired.
Claims
exact text as granted — not AI-modified1 - 12 . (canceled)
13 . An isolated NKT cell, wherein said cell has been activated by at least one phosphatidylinositol mannoside (PIM).
14 . An isolated NKT cell as claimed in claim 13 , further comprising a pharmaceutically acceptable vehicle.
15 . An isolated NKT cell as claimed in claim 13 , wherein said PIM is of mycobacterial origin.
16 . An isolated NKT cell as claimed in claim 13 , wherein said PIM is obtained from Mycobacterium tuberculosis.
17 . An isolated NKT cell as claimed in claim 13 , wherein said PIM comprises 4, 5, or 6 mannose units.
18 . An isolated NKT cell as claimed in claim 13 , wherein said PIM comprises the formula:
wherein:
R 1 is a hydroxyl group or a (Man) x group,
R 2 is a hydroxyl group or a (Man) x group,
R 3 is a hydroxyl group or a (Man) x group,
R 4 is a hydroxyl group or a (Man) x group,
R 5 is a hydroxyl group or a (Man) x group,
R 6 is optionally a fatty acid residue, and
R 7 is optionally a fatty acid residue;
and wherein said (Man) x group is at least one mannoside group linked to inositol and x is the number of mannose units attached to one another in linear fashion.
19 . An isolated NKT cell as claimed in claim 18 , wherein the number of mannose units is 1, 2, 3, 4, 5, or 6.
20 . An isolated NKT cell as claimed in claim 18 , wherein the fatty acid residue comprises 18 to 24 carbon atoms.
21 . An isolated NKT cell as claimed in claim 18 , wherein the fatty acid residue lacks a double bond.
22 . An isolated NKT cell as claimed in claim 18 , wherein the fatty acid residue lacks a polar substituent.
23 . An isolated NKT cell as claimed in claim 18 , wherein any two of R 1 , R 2 , R 3 , R 4 , and R 5 are each said (Man) x group and the remaining three groups are each said hydroxyl group.
24 . An isolated NKT cell as claimed in claim 23 , wherein the two (Man) x groups are adjacent to one another.
25 . An isolated NKT cell as claimed in claim 18 , wherein:
R 1 is a hydroxyl group, R 2 is a (Man) x group, R 3 is a (Man) x group, R 4 is a hydroxyl group, and R 5 is a hydroxyl group.
26 . An isolated NKT cell as claimed in claim 18 , wherein:
R 1 is a hydroxyl group, R 2 is a (Man) x group, wherein x is 1, R 3 is a (Man) x group, wherein x is 1, 2, 3, 4, 5, or 6, R 4 is a hydroxyl group, and R 5 is a hydroxyl group.
27 . A pharmaceutical composition comprising at least one phosphatidylinositol mannoside (PIM)-activated NKT cell and a pharmaceutically acceptable vehicle.
28 . A pharmaceutical composition as claimed in claim 27 , wherein said PIM is of mycobacterial origin.
29 . A pharmaceutical composition as claimed in claim 27 , wherein said PIM is obtained from Mycobacterium tuberculosis.
30 . A pharmaceutical composition as claimed in claim 27 , wherein said PIM comprises 4, 5, or 6 mannose units.
31 . A pharmaceutical composition as claimed in claim 27 , wherein said PIM comprises the formula:
wherein:
R 1 is a hydroxyl group or a (Man) x group,
R 2 is a hydroxyl group or a (Man) x group,
R 3 is a hydroxyl group or a (Man) x group,
R 4 is a hydroxyl group or a (Man) x group,
R 5 is a hydroxyl group or a (Man) x group,
R 6 is optionally a fatty acid residue, and
R 7 is optionally a fatty acid residue;
and wherein said (Man) x group is at least one mannoside group linked to inositol and x is the number of mannose units attached to one another in linear fashion.
32 . A pharmaceutical composition as claimed in claim 31 , wherein the number of mannose units is 1, 2, 3, 4, 5, or 6.
33 . A pharmaceutical composition as claimed in claim 31 , wherein the fatty acid residue comprises 18 to 24 carbon atoms.
34 . A pharmaceutical composition as claimed in claim 31 , wherein the fatty acid residue lacks a double bond.
35 . A pharmaceutical composition as claimed in claim 31 , wherein the fatty acid residue lacks a polar substituent.
36 . A pharmaceutical composition as claimed in claim 31 , wherein any two of R 1 , R 2 , R 3 , R 4 , and R 5 are each said (Man) x group and the remaining three groups are each said hydroxyl group.
37 . A pharmaceutical composition as claimed in claim 36 , wherein the two (Man) x groups are adjacent to one another.
38 . A pharmaceutical composition as claimed in claim 31 , wherein:
R 1 is a hydroxyl group, R 2 is a (Man) x group, R 3 is a (Man) x group, R 4 is a hydroxyl group, and R 5 is a hydroxyl group.
39 . A pharmaceutical composition as claimed in claim 31 , wherein:
R 1 is a hydroxyl group, R 2 is a (Man) x group, wherein x is 1, R 3 is a (Man) x group, wherein x is 1, 2, 3, 4, 5, or 6, R 4 is a hydroxyl group, and R 5 is a hydroxyl group.
40 . A method of treating a disease in a human in which an immune reaction of the granulomatous type is desired, comprising administering to the human at least one phosphatidylinositol mannoside (PIM), at least one PIM-activated NKT cell, or at least one PIM and at least one PIM-activated NKT cell.
41 . A method of treating a disease in a human as claimed in claim 40 , wherein said PIM is of mycobacterial origin.
42 . A method of treating a disease in a human as claimed in claim 40 , wherein said PIM is obtained from Mycobacterium tuberculosis.
43 . A method of treating a disease in a human as claimed in claim 40 , wherein said PIM comprises 4, 5, or 6 mannose units.
44 . A method of treating a disease in a human as claimed in claim 40 , wherein said PIM comprises the formula:
wherein:
R 1 is a hydroxyl group or a (Man) x group,
R 2 is a hydroxyl group or a (Man) x group,
R 3 is a hydroxyl group or a (Man) x group,
R 4 is a hydroxyl group or a (Man) x group,
R 5 is a hydroxyl group or a (Man) x group,
R 6 is optionally a fatty acid residue, and
R 7 is optionally a fatty acid residue;
and wherein said (Man) x group is at least one mannoside group linked to inositol and x is the number of mannose units attached to one another in linear fashion.
45 . A method of treating a disease in a human as claimed in claim 44 , wherein the number of mannose units is 1, 2, 3, 4, 5, or 6.
46 . A method of treating a disease in a human as claimed in claim 44 , wherein the fatty acid residue comprises 18 to 24 carbon atoms.
47 . A method of treating a disease in a human as claimed in claim 44 , wherein the fatty acid residue lacks a double bond.
48 . A method of treating a disease in a human as claimed in claim 44 , wherein the fatty acid residue lacks a polar substituent.
49 . A method of treating a disease in a human as claimed in claim 44 , wherein any two of R 1 , R 2 , R 3 , R 4 , and R 5 are each said (Man) x group and the remaining three groups are each said hydroxyl group.
50 . A method of treating a disease in a human as claimed in claim 49 , wherein the two (Man) x groups are adjacent to one another.
51 . A method of treating a disease in a human as claimed in claim 44 , wherein:
R 1 is a hydroxyl group, R 2 is a (Man) x group, R 3 is a (Man) x group, R 4 is a hydroxyl group, and R 5 is a hydroxyl group.
52 . A method of treating a disease in a human as claimed in claim 44 , wherein:
R 1 is a hydroxyl group, R 2 is a (Man) x group, wherein x is 1, R 3 is a (Man) x group, wherein x is 1, 2, 3, 4, 5, or 6, R 4 is a hydroxyl group, and R 5 is a hydroxyl group.
53 . A method of treating a disease in a human as claimed in claim 40 , wherein said disease is caused by an infection with a bacterial agent.
54 . A method of treating a disease in a human as claimed in claim 53 , wherein said bacterial agent is a mycobacteria.
55 . A method of treating a disease in a human as claimed in claim 40 , wherein said disease is a cancer.
56 . A method of treating a disease in a human as claimed in claim 40 , wherein said disease is a melanoma.Join the waitlist — get patent alerts
Track US2006263376A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.